No Cover Image

Journal article 373 views 72 downloads

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Mansoor Husain, Steve Bain Orcid Logo, Ole K. Jeppesen, Ildiko Lingvay, Rasmus Sørrig, Marianne B. Treppendahl, Tina Vilsbøll

Diabetes, Obesity and Metabolism, Volume: 22, Issue: 3, Pages: 442 - 451

Swansea University Author: Steve Bain Orcid Logo

  • 53094.pdf

    PDF | Version of Record

    Released under the terms of a Creative Commons Attribution-NonCommercial License (CC-BY-NC).

    Download (950.96KB)

Check full text

DOI (Published version): 10.1111/dom.13955

Published in: Diabetes, Obesity and Metabolism
ISSN: 1462-8902 1463-1326
Published: Wiley 2020
Online Access: Check full text

Tags: Add Tag
No Tags, Be the first to tag this record!
Keywords: cardiovascular disease, clinical trial, glucagon-like peptide-1 analogue, phase III study, type 2 diabetes
College: Faculty of Medicine, Health and Life Sciences
Issue: 3
Start Page: 442
End Page: 451